Prevalence of Bronchiectasis in COPD Patients

NCT ID: NCT04101448

Last Updated: 2019-09-24

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-09-30
• Study Completion Date: 2020-09-30

Brief Summary

The identification of bronchiectasis in COPD has been defined as a different clinical COPD phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. A causal association has not yet been proven, but it is biologically plausible that COPD, and particularly the infective and exacerbator COPD phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity.

Detailed Description

The relationship between bronchiectasis and COPD has generated several questions. Is there any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in COPD, to the extent that it can be considered a distinct clinical phenotype? Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a consequence of the disease's natural history? Is there a causal relationship between COPD and bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible for this relationship? And, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?

Conditions

Bronchiectasis; Chronic Obstruct Airways Disease; Prognosis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Group A

COPD patients with bronchiectasis

prevalence

Intervention Type: OTHER

percentage of bronchectasis in COPD and its effect as prognostic measure

Group B

COPD patients without bronchiectasis

prevalence

Intervention Type: OTHER

percentage of bronchectasis in COPD and its effect as prognostic measure

Interventions

prevalence

percentage of bronchectasis in COPD and its effect as prognostic measure

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• COPD patients based on GOLD 2019 criteria, stable or in exacerbation

Exclusion Criteria

• acute pneumonia within 2 months
• malignancy
• congenital bronchiectasis ( immobile cilia syndrome, Kartagnar syndrome).
• Pregnancy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Aliae AR Mohamed Hussein

Professor of Pulmonology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

AssiutU

Asyut, , Egypt

Site Status: RECRUITING

Countries

Egypt

Central Contacts

Aliae Mohamed-Hussein

Role: CONTACT

aliaehussein@gmail.com

01222302352 ext. 002

Facility Contacts

Aliae AR Mohamed-Hussein

Role: primary

aliaehussein@gmail.com

+201222302352

Other Identifiers

AssiutU7

Identifier Type: -

Identifier Source: org_study_id